MIAMI, Oct. 24, 2011 /PRNewswire/ -- Internal Fixation Systems, Inc. (OTC QB: IFIX) today announces that it has commenced offering for sale the initial modules (consisting of basic instruments and screws and 1/3 tubular plates) of its U.S. Food and Drug Administration (FDA) approved small fragment system which will be used to treat bone fractures and osteotomies. “We believe our new modular set design is innovative in the industry,” said Internal Fixation Systems President and CEO, Stephen Dresnick, MD. “Rather than have large sets with multiple types of plates, our system makes more efficient use of inventory by standardizing instruments and surgical trays across product lines. This allows us to pass along greater savings to our customers and ultimately to patients.
About IFS: Internal Fixation Systems, Inc is a manufacturer and marketer of high quality, responsibly priced orthopedic and podiatric implants. We seek to prove that superior products and lower costs can go hand in hand. IFS focuses on widely used, market proven products used to treat common fractures. Our Advisory Panel, consisting of nationally recognized surgeons, provides input on how to improve our implant designs. The resulting products incorporate doctor requested enhancements and are priced at 40-60% less than the competition. IFS customers include ambulatory surgery centers, hospitals and orthopedic surgeons. Please contact us for more information about our product and business model.
This press release contains projections and forward-looking information that involve various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of Internal Fixation, such as whether we sell our new product offering There are numerous risks and uncertainties that could cause actual results and Internal Fixation’s plans and objectives to differ materially from those expressed in the forward-looking information, including whether Internal Fixation will have sufficient capital to continue its operations.. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and views of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, IFS does not intend to update these forward-looking statements.
For further information, please contact: | Laura Cattabriga, Chief Financial Officer | ||
Tel: 786 268 0995 | |||
SOURCE Internal Fixation Systems, Inc.